CY1112000T1 - ΠΡΩΤΕΑΣΗ ΔΙΑΣΠΑΣΗΣ ΤΟΥ ΠΑΡΑΓΟΝΤΑ VON WILLEBRAND (vWF) - Google Patents

ΠΡΩΤΕΑΣΗ ΔΙΑΣΠΑΣΗΣ ΤΟΥ ΠΑΡΑΓΟΝΤΑ VON WILLEBRAND (vWF)

Info

Publication number
CY1112000T1
CY1112000T1 CY20111101087T CY111101087T CY1112000T1 CY 1112000 T1 CY1112000 T1 CY 1112000T1 CY 20111101087 T CY20111101087 T CY 20111101087T CY 111101087 T CY111101087 T CY 111101087T CY 1112000 T1 CY1112000 T1 CY 1112000T1
Authority
CY
Cyprus
Prior art keywords
leu
vwf
val
ala
protease
Prior art date
Application number
CY20111101087T
Other languages
English (en)
Inventor
Kenji Soejima
Noriko Mimura
Hiroaki Maeda
Chikateru Nozaki
Takayoshi Hamamoto
Tomohiro Nakagaki
Original Assignee
Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute filed Critical Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute
Publication of CY1112000T1 publication Critical patent/CY1112000T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Η παρούσα εφεύρεση εστιάζεται στην απομόνωση και ταυτοποίηση vWF- επιλεκτικής πρωτεάσης διάσπασης. Η vWF-επιλεκτική πρωτεάση διάσπασης διασπά δεσμό μεταξύ λειμμάτων Tyr 842 και Met 843 του vWF και περιλαμβάνει πολυπεπτιδική αλυσίδα έχουσα Leu-Leu-Val-Ala-Val ως μερική αλληλλουχία, και κατά περαιτέρω προτίμηση περιλαμβάνει πολυπεπτιδική αλυσίδα έχουσα τη μερική Ν-τερματική αμινοξυαλληλουχία ώριμης πρωτεΐνης, Ala-Ala-Gly-Gly-He-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val, και έχουσα μοριακό βάρος 105 έως 160 kDa σε SDS-PAGE υπό αναγωγικές ή μη αναγωγικές συνθήκες. Η απομόνωση και η ταυτοποίηση αυτής της vWF-επιλεκτικής πρωτεάσης διάσπασης οδήγησε στη δυνατότητα θεραπείας υποκατάστασης για ασθενείς με παθήσεις οφειλόμενες σε ανεπάρκεια της πρωτεάσης, όπως θρομβωτική θρομβοκυτταροπενική πορφύρα.
CY20111101087T 2001-04-25 2011-11-11 ΠΡΩΤΕΑΣΗ ΔΙΑΣΠΑΣΗΣ ΤΟΥ ΠΑΡΑΓΟΝΤΑ VON WILLEBRAND (vWF) CY1112000T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001128342 2001-04-25
JP2001227510 2001-07-27
JP2001302977 2001-09-28
JP2002017596 2002-01-25
EP08156811A EP1956093B1 (en) 2001-04-25 2002-04-25 von Willebrand Factor (vWF)-cleaving protease

Publications (1)

Publication Number Publication Date
CY1112000T1 true CY1112000T1 (el) 2015-11-04

Family

ID=27482239

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101087T CY1112000T1 (el) 2001-04-25 2011-11-11 ΠΡΩΤΕΑΣΗ ΔΙΑΣΠΑΣΗΣ ΤΟΥ ΠΑΡΑΓΟΝΤΑ VON WILLEBRAND (vWF)

Country Status (13)

Country Link
US (4) US7112666B2 (el)
EP (2) EP1391516A4 (el)
JP (3) JP2003284570A (el)
KR (1) KR101047604B1 (el)
CN (2) CN100537770C (el)
AT (1) ATE525471T1 (el)
AU (2) AU2008201773B2 (el)
CA (1) CA2445421C (el)
CY (1) CY1112000T1 (el)
DK (1) DK1956093T3 (el)
ES (1) ES2373482T3 (el)
PT (1) PT1956093E (el)
WO (1) WO2002088366A1 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
DE60331666D1 (de) * 2002-09-25 2010-04-22 Chemo Sero Therapeut Res Inst Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon
ATE486936T1 (de) * 2003-03-05 2010-11-15 Chemo Sero Therapeut Res Inst Verfahren zur herstellung eines heterologen proteins in e. coli
WO2004083250A1 (ja) * 2003-03-17 2004-09-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物
US8088624B2 (en) 2003-12-22 2012-01-03 Mitsubishi Kagaku Iatron, Inc. Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
EP1852442B1 (en) * 2005-02-14 2012-03-14 Alfresa Pharma Corporation Antibody for assay of adamts13 activity and method of activity assay
PL1902141T3 (pl) 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
JP5067917B2 (ja) * 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
WO2009001743A1 (ja) 2007-06-22 2008-12-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 新規adamts-13改変体
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US20090317375A1 (en) * 2008-05-12 2009-12-24 Immune Disease Institute, Inc. Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
EP3388529A1 (en) * 2008-12-05 2018-10-17 Baxalta GmbH Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
CN102573792B (zh) 2009-09-21 2014-10-15 巴克斯特国际公司 稳定化的液体和冻干的adamts13制剂
US8759293B2 (en) * 2009-11-13 2014-06-24 Grifols Therapeutics Inc. von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2015021552A1 (en) * 2013-08-14 2015-02-19 National Research Council Of Canada Clipped amplifier
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
EP3526339A1 (en) 2016-10-11 2019-08-21 Laboratory Corporation of America Holdings Methods and systems for determining adamts13 enzyme activity
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4437544A1 (de) 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
US20010049106A1 (en) * 2000-04-27 2001-12-06 Leonard Buckbinder ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
AU2002218196A1 (en) * 2000-09-28 2002-04-08 Bayer Aktiengesellschaft Regulation of human adam-ts-like protein
US20020151702A1 (en) * 2000-10-18 2002-10-17 Genetics Institute, Inc. Aggrecanase molecules
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
DE60331666D1 (de) * 2002-09-25 2010-04-22 Chemo Sero Therapeut Res Inst Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon

Also Published As

Publication number Publication date
EP1391516A4 (en) 2004-07-14
AU2008243279A1 (en) 2008-12-04
ATE525471T1 (de) 2011-10-15
CN1537167A (zh) 2004-10-13
AU2008201773A1 (en) 2008-05-15
US20080254527A1 (en) 2008-10-16
JP2008109938A (ja) 2008-05-15
EP1956093B1 (en) 2011-09-21
WO2002088366A1 (fr) 2002-11-07
US7112666B2 (en) 2006-09-26
US7361748B2 (en) 2008-04-22
ES2373482T3 (es) 2012-02-03
AU2008201773B2 (en) 2008-12-18
CN100537770C (zh) 2009-09-09
JP4163517B2 (ja) 2008-10-08
CA2445421C (en) 2012-08-07
JPWO2002088366A1 (ja) 2004-08-19
US20060073569A1 (en) 2006-04-06
AU2008243279B2 (en) 2012-06-14
CA2445421A1 (en) 2002-11-07
KR101047604B1 (ko) 2011-07-07
AU2008201773A8 (en) 2008-05-22
US8067221B2 (en) 2011-11-29
DK1956093T3 (da) 2012-01-16
PT1956093E (pt) 2011-12-30
CN101613688A (zh) 2009-12-30
EP1391516A1 (en) 2004-02-25
US20130041137A1 (en) 2013-02-14
JP2003284570A (ja) 2003-10-07
US20040214275A1 (en) 2004-10-28
KR20040015163A (ko) 2004-02-18
EP1956093A1 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
CY1112000T1 (el) ΠΡΩΤΕΑΣΗ ΔΙΑΣΠΑΣΗΣ ΤΟΥ ΠΑΡΑΓΟΝΤΑ VON WILLEBRAND (vWF)
Nishida et al. Purification and characterization of bothrombin, a fibrinogen-clotting serine protease from the venom of Bothrops jararaca
NO20011386L (no) Nye fremgangsmåter for fremvisning av (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
DE60137710D1 (de) VON-WILLEBRAND-FAKTOR (vWF) SPALTENDES PROTEASE-POLYPEPTID, FÜR DAS POLYPEPTID CODIERENDE NUKLEINSÄURE UND VERWENDUNG DES POLYPEPTIDS
DE3874798T2 (de) Therapeutisches proteinagens in form von aerosol.
HK1080517A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
ATE368053T1 (de) Antimikrobielle peptide
Oshikawa et al. Ussuristatin 2, a novel KGD-bearing disintegrin from Agkistrodon ussuriensis venom
SI1511770T1 (sl) Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezni
FR2831170B1 (fr) Proteines c modifiees activables directement par la thrombine
BG104267A (en) Aminoterminally incised rantes as haemokin antagonists
ATE540108T1 (de) Familie gh 61 polypeptiden
DE69733773D1 (de) Fas ANTIGEN-DERIVATE
Della-Casa et al. Insularin, a disintegrin from Bothrops insularis venom: inhibition of platelet aggregation and endothelial cell adhesion by the native and recombinant GST-insularin proteins
ATE111484T1 (de) Verbindungen zur verhinderung von thrombose.
DE60313982D1 (de) Dimere von thrombinpeptidderivaten
DE69940927D1 (de) PEPTIDFRAGMENTE MIT DEN ZELLTOD VERHINDERNDEr AKTIVITÄT
Bonnefoy et al. Thrombospondin-1 in von Willebrand factor function
DK270489D0 (da) Protein med thrombininhiberende virkning, fremgangsmaade til dets isolering, samt dets anvendelse som laegemiddel
ATE448793T1 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
EP1634954A4 (en) PROTEASE, PROTEASE-CODING DNA AND PROCESS FOR PREPARING THE PROTEASE
Henschen et al. Structure-function-evolution relationship in fibrinogen
DE69623803T2 (de) Verwendung von KASEINFRAGMENTEn als WACHSTUMERFÖRDERer
DE58909261D1 (de) Ancrod-proteine, ihre herstellung und verwendung.
Moradian-Oldak et al. Limited proteolysis of amelogenin: toward understanding the proteolytic processes in enamel extracellular matrix